Cite
Shi J, Chen G, Wang H, et al. Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial. Thorac Cancer. 2021;12(17):2345-2351doi: 10.1111/1759-7714.14076.
Shi, J., Chen, G., Wang, H., Wang, X., Han, B., Li, K., Wang, Q., Zhang, L., Wang, Z., Cheng, Y., He, J., Shi, Y., Chen, W., Luo, Y., Wu, L., Wang, X., Nan, K., Jin, F., Dong, J., Li, B., & Liu, Z. (2021). Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial. Thoracic cancer, 12(17), 2345-2351. https://doi.org/10.1111/1759-7714.14076
Shi, Jianhua, et al. "Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial." Thoracic cancer vol. 12,17 (2021): 2345-2351. doi: https://doi.org/10.1111/1759-7714.14076
Shi J, Chen G, Wang H, Wang X, Han B, Li K, Wang Q, Zhang L, Wang Z, Cheng Y, He J, Shi Y, Chen W, Luo Y, Wu L, Wang X, Nan K, Jin F, Dong J, Li B, Liu Z. Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial. Thorac Cancer. 2021 Sep;12(17):2345-2351. doi: 10.1111/1759-7714.14076. Epub 2021 Jul 17. PMID: 34273139; PMCID: PMC8410552.
Copy
Download .nbib